（文章来源：证券日报） 证券日报网讯 12月16日，福安药业在互动平台回答投资者提问时表示，截至12月10日，公司股东户数 为38855户。 ...

有消息称特朗普预计将指示政府推进将大麻重新归类为危害较低的药物，这一举措可能成为数十年来美 国大麻政策最重大的转变之一。知情人士称，特朗普已经与大麻行业高管、卫生与公众服务部部长小罗 伯特·F·肯尼迪，以及医疗保险与医疗补助服务中心(CMS)负责人Mehmet Oz讨论了这一想法。一位白宫官 员表示，关于重新分类的最终决定尚未作出。重新分类将使购买和销售大麻变得更加容易，大麻企业一 直在游说政府推动改革，而重新分类的决定可能会减轻税负和银行服务方面的障碍。 格隆汇12月12日｜A股市场工业大麻概念股走强，其中，顺灏股份涨停，福安药业、蓝晓科技、金鹰股份 涨超4%，诚益通、永吉股份、晨光生物涨超3%。 | | | | | 工业大麻板块个股 | | | | --- | --- | --- | --- | --- | --- | --- | | 序号 | 代码 | 名称 | 8 | 涨幅%↓ | 总市值 | 年初至今涨幅% | | 1 | 002565 | 顺灏股份 | 中 | 10.00 | 169亿 | 428.79 | | 2 | 300194 | 福安药业 | | 4.91 | 55.92亿 | 7.16 ...

Group 1 - Jicheng Electronics won a total of 15 bids from the State Grid Corporation, with a total bid amount of approximately 215 million yuan, accounting for 8.27% of the company's projected revenue for 2024 [2] - Jianmin Group's chemical generic drug, Ambrutoro Oral Solution, has been approved for market launch by the National Medical Products Administration, aimed at treating cough and wheezing caused by chronic bronchitis and emphysema [3] - Taiji Industry's subsidiary plans to transfer accounts receivable not exceeding 85 million USD to optimize cash flow, with an expected service fee of approximately 285,000 USD [4] Group 2 - Nanjing Pharmaceutical's subsidiary plans to invest 398 million yuan in a modern pharmaceutical logistics expansion project, with a construction period of approximately 35 months [5] - Ruili Kemi received a development notification from a well-known domestic flying car company to supply core components [6] - Ding Tong Technology announced that several executives plan to reduce their holdings by a total of no more than 45,300 shares, representing about 0.032% of the total share capital [7][8] Group 3 - Ninghu Expressway's subsidiary plans to invest no more than 9.033 billion yuan in the construction of the Nanyang Yangtze River Bridge South Connection Project [10] - Wuliangye announced a mid-term profit distribution plan for 2025, proposing a cash dividend of 25.78 yuan per 10 shares, totaling approximately 10 billion yuan [12] - Beixin Road and Bridge's subsidiary won a bid for a project worth 180 million yuan [14] Group 4 - Minhe Livestock reported a 7.75% month-on-month increase in sales revenue from commodity chick sales in November [15] - Xuelong Group plans to invest 100 million yuan to establish a wholly-owned subsidiary for vertical integration in the aluminum and magnesium technology sector [16] - Shengnong Development reported a 15.77% year-on-year increase in sales revenue in November, with significant growth in both poultry and processed meat products [17] Group 5 - Xingyu Co., Ltd. plans to repurchase shares worth 200 million to 300 million yuan for employee stock ownership plans [18] - Quan Chai Power intends to use 50 million yuan of idle funds to purchase structured deposit products [19] - Shibei High-tech appointed Zhao Junhong as the new deputy general manager [20] Group 6 - Fuan Pharmaceutical's subsidiary received a drug registration certificate for injectable isavuconazole, expanding its anti-infection product line [21] - Xiaoming Co. reported a 49.73% year-on-year decline in chicken product sales revenue in November [22] - Baiao Chemical adjusted its share repurchase price ceiling to no more than 48.95 yuan per share [23] Group 7 - Hefei China reported a 26.02% year-on-year decline in consolidated revenue for the first 11 months [24] - Laimei Pharmaceutical's subsidiary received medical device registration certificates for two endoscope products [25][26] - Xiantan Co. reported an 11.63% year-on-year increase in chicken product sales revenue in November [27] Group 8 - Qilin Security received government subsidies totaling 5.4014 million yuan [28] - Blue Sky Gas's controlling shareholder's 30.9134 million shares were judicially frozen, accounting for 4.33% of the total share capital [29] - Tieke Railway signed a contract for high-speed railway fasteners worth 654 million yuan, accounting for 41.08% of the company's projected revenue for 2024 [30] Group 9 - David Medical's electric surgical table received a medical device registration certificate [31] - Zhendong Pharmaceutical's affiliate's core product new drug application was accepted by the CDE [32] - Shanghai Pharmaceutical's apple acid sitagliptin tablet application for market approval was granted by the National Medical Products Administration [33] Group 10 - Nanjiao Food reported a 1.14% year-on-year increase in consolidated revenue for November [34]

福安药业（300194）(300194.SZ)公告，公司全资子公司福安药业集团湖北人民制药有限公司(简称"人民 制药")于近日收到国家药品监督管理局签发的药品注册证书，药品名称：注射用硫酸艾沙康唑。注射用 硫酸艾沙康唑适用于治疗成人患者下列感染：侵袭性曲霉病;侵袭性毛霉病。 ...

格隆汇12月10日丨福安药业(300194.SZ)公布，全资子公司福安药业集团湖北人民制药有限公司于近日 收到国家药品监督管理局签发的药品注册证书，药品名称：注射用硫酸艾沙康唑。注射用硫酸艾沙康唑 适用于治疗成人患者下列感染：侵袭性曲霉病；侵袭性毛霉病。根据国家药品监督管理局数据查询信息 平台显示，截止目前，该药品共有11家企业（含人民制药）通过一致性评价或视同通过一致性评价。 ...

福安药业12月10日公告，公司全资子公司福安药业集团湖北人民制药有限公司收到国家药品监督管理局 签发的药品注册证书，药品名称为注射用硫酸艾沙康唑，注册分类为化药4类，规格为0.2g。该药品适 用于治疗成人患者侵袭性曲霉病和侵袭性毛霉病。截至目前，共有11家企业（含人民制药）通过一致性 评价或视同通过一致性评价。药品注册证书的获得将进一步丰富子公司产品线，提升市场竞争力，但受 行业政策、市场环境变化等因素影响，产品的生产、销售情况以及对公司业绩的具体影响存在不确定 性。 ...

人民财讯12月10日电，福安药业（300194）12月10日公告，公司全资子公司福安药业集团湖北人民制药 有限公司于近日收到国家药品监督管理局签发的注射用硫酸艾沙康唑药品注册证书。注射用硫酸艾沙康 唑适用于治疗成人患者下列感染：侵袭性曲霉病；侵袭性毛霉病。 ...

证券代码：300194 证券简称：福安药业 公告编号：2025-044 福安药业（集团）股份有限公司 关于子公司收到药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假 记载、误导性陈述或者重大遗漏。 福安药业（集团）股份有限公司（以下简称"公司"）全资子公司福安药业集 团湖北人民制药有限公司（以下简称"人民制药"）于近日收到国家药品监督管 理局签发的药品注册证书，现将具体情况公告如下： | 注射用硫酸艾 沙康唑 | 化药 4 | 类 | 0.2g | 人民制药 | 国药准字 | 经审查，本品符合药品注册的有关要 | | --- | --- | --- | --- | --- | --- | --- | | 药品名称 | 注册分类 | | 规格 | 药品上市许 可持有人 | 批准文号 H20256127 | 审批结论 求，批准注册，发给药品注册证书。 | 注射用硫酸艾沙康唑适用于治疗成人患者下列感染：侵袭性曲霉病；侵袭性 毛霉病。根据国家药品监督管理局数据查询信息平台显示，截止目前，该药品共 有 11 家企业（含人民制药）通过一致性评价或视同通过一致性评价。 上述药品注册证 ...

证券日报网讯 12月8日晚间，福安药业发布公告称，2025年12月7日，国家医保局、人力资源社会保障 部发布了《关于印发 （2025年）的通知》【医保发〔2025〕33号）】，药品名称：帕拉米韦注射液。 （文章来源：证券日报） ...

剑桥科技：拟出资4亿元参与设立光器件与芯片产业基金 12月8日晚，剑桥科技(603083)发布公告称，公司拟使用H股募集资金4亿元，受让并增资入伙扬中幸福 家园创业投资合伙企业（有限合伙），交易完成后将持有该基金99.9975%的份额，并将其纳入合并报 表范围。该基金聚焦光器件、芯片及核心IC等硬科技领域，主要投资初创期和成长期企业。 隧道股份：联合体中标64.9亿元河南高速公路特许经营项目 12月8日晚，隧道股份(600820)发布公告称，公司下属五家子公司组成的联合体于12月8日正式中标"辉 县至鄄城（豫鲁界）高速公路辉县至卫辉段项目"特许经营者。项目总投资64.9亿元，采用BOT模式， 合作期33.25年（含建设期3.5年、收费期29.75年），将负责全长50.32公里的四车道高速建设与运营。 宏润建设：中标2.3亿元工程 12月8日晚，宏润建设(002062)发布公告称，公司于近日收到中标通知书，杭州市城市轨道交通18号线 一期工程车站（含区间）设备安装及装修工程I标段项目由公司中标承建，工程中标价2.3亿元。该工程 中标价占公司2024年度营业收入的3.88%。 同仁堂：产品参苓白术散获得加拿大产品 ...